Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 5c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.85), $0.05 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $20 million versus the consensus estimate of $19.44 million.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM
• Pfizer lung cancer drug misses survival goal in Phase 3 trial